Acrivon Therapeutics GAAP EPS of -$0.42 beats by $0.02
Acrivon Therapeutics (ACRV) reported Q3 GAAP EPS of -$0.42, beating estimates by $0.02. The company has $77.8M in cash and investments, expected to last until Q4 2027. Shares fell 2.05% after hours.
How this was made

The 30-second read
Why it matters
The EPS beat can improve near-term sentiment, while the stated funding runway into Q4 2027 reduces balance-sheet overhang and may lower perceived dilution risk.
Market read
Traders can update positioning around earnings expectations and funding-risk assumptions based on the EPS beat and the runway statement.
What to watch
The article does not include revenue, guidance, or segment/clinical catalysts, which are often the primary drivers of post-earnings repricing in biotech.
Background
The piece summarizes Acrivon Therapeutics’ Q3 GAAP EPS result and provides a cash/investments runway estimate.
Ticker impact
Acrivon Therapeutics reported Q3 GAAP EPS of -$0.42, beating by $0.02, and disclosed $77.8M cash/investments expected to fund operations into Q4 2027.
Shares may see modest upside or reduced downside as the market digests the EPS beat and longer funding horizon.
The article provides a concrete earnings datapoint (GAAP EPS beat) plus a balance-sheet runway statement, both directly tied to investor risk and valuation.
Market effects
Biotech investors may recalibrate funding-risk expectations for small-cap drug developers when cash runway is extended.
Limited, single-company earnings impact.
Low, no cross-market policy or macro linkage indicated.
Counterpoint
Despite the EPS beat, the company still reported negative GAAP earnings, so the market may focus on burn rate and whether the runway is sufficient for upcoming clinical or commercialization milestones.
Key entities
- companyAcrivon Therapeutics
Reported Q3 GAAP EPS of -$0.42 (beat by $0.02) and disclosed $77.8M cash, cash equivalents and investments as of Sept. 30, 2026.
